Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 11/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27254053 | 0.83 | DHFR (0.50) | HTTDHFRSMN1; SMN2KDM4ERAD52 | |
| SCHEMBL8139053 | 0.79 | ALDH1A1 (0.41) | HTTSMN1; SMN2KDM4ERAD52RAB9A | |
| SCHEMBL2757284 | 0.79 | DHFR (0.45) | DHFRSMN1; SMN2KDM4ERAD52RAB9A | |
| SCHEMBL11609819 | 0.77 | HTT (0.50) | HTTDHFRSMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3778992 | 0.77 | HTT (0.64) | HTTSMN1; SMN2KDM4ERAD52ALDH1A1 | |
| SCHEMBL4230732 | 0.76 | HTT (0.53) | HTTDHFR | |
| SCHEMBL611438 | 0.76 | POLB (0.59) | HTTSMN1; SMN2KDM4ERAD52ALDH1A1 | |
| SCHEMBL29642054 | 0.76 | POLB (0.59) | HTTSMN1; SMN2KDM4ERAD52ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5251194 | 0.74 | POLB (0.62) | HTTSMN1; SMN2KDM4ERAD52ALDH1A1 | |
| SCHEMBL11610905 | 0.73 | HTT (0.39) | HTTDHFRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1749250-A | Chemical synthetic method for 2-chloro-4-amino-6,7-dimethoxy quinazoline | DIANHUA GROUP CO LTD HANGZHOU (CN) | 2006-03-22 | — | — | CN | claimed |
| WO-2024101337-A1 | QUINAZOLINE DERIVATIVES | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| CN-1749250-A | Chemical synthetic method for 2-chloro-4-amino-6,7-dimethoxy quinazoline | DIANHUA GROUP CO LTD HANGZHOU (CN) | 2006-03-22 | — | — | CN | disclosed |
| CN-1749250-A | Chemical synthetic method for 2-chloro-4-amino-6,7-dimethoxy quinazoline | DIANHUA GROUP CO LTD HANGZHOU (CN) | 2006-03-22 | — | — | CN | disclosed |
| EP-1315714-B1 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-6559153-B2 | 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders | SYNTEX (U.S.A.) LLC | 2003-05-06 | — | — | US | disclosed |
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | SYNTEX (U.S.A.) LLC | 2002-04-18 | — | — | US | disclosed |
| US-4098788-A | Process for preparing quinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | ADRB1, ADRA1B, ADRA1D | HTT 4360/4885DHFR 1632/4885SMN1; SMN2 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.